Podium to Practice: Chicago 2025 – GU: Checkmate 9ER

Podium to Practice: Chicago 2025 – GU: Checkmate 9ER

Podium to Practice: Chicago 2025
Explore more from your favourite experts – click their name to access their entire library of content.
Icon Chair Speaker

Chair

Dr. Sebastien Hotte

Icon Chair Speaker

Speakers

Dr. Nimira Alimohamed

Dr. Maria Jiang

Studies / Trials Discussed

4511 – An integrative analysis of circulating and tumor microenvironment (TME) determinants of patient response in the Checkmate 9ER (CM 9ER) trial of nivolumab and cabozantinib (NIVO+CABO) in advanced renal cell carcinoma (aRCC).

This program has been made possible through unrestricted support from Ipsen.

Studies/trials discussed:

4511 – An integrative analysis of circulating and tumor microenvironment (TME) determinants of patient response in the Checkmate 9ER (CM 9ER) trial of nivolumab and cabozantinib (NIVO+CABO) in advanced renal cell carcinoma (aRCC).
Tagged